April 1, 2026 09:29 AM GMT Jiangsu Hengrui | Asia Pacific China Summit 2026 Feedback Key Takeaways Updates on the Incretin portfolio: Ahead of the expected early-2027 launch of HRS-9531 (GLP-1/GIP injectable), mgmt reiterated its superior safety profile and the potentially broader metabolic benefits under study, and views HRS-9531 as a top-10 sales contributor by 2028. Overseas, NewCo Kailera initiated a global Ph3 trial in January 2026. Key immunology assets: Mgmt highlighted IL23p19/IL36R for PsO, UC, and ...